Kidney injury induced by sunitinib

Di Zhang,Ying Zhou,Yimin Cui,Yan Liang

DOI: https://doi.org/10.3760/cma.j.issn.1008-5734.2015.06.013

2015-01-01

Abstract:A 52-year-old male patient with suprarenal epithelioma started to receive the targeted therapy of sunitinib(50 mg daily for 4 weeks,then at an interval of 2 weeks,six weeks for 1 cycle)one month after the right nephrectomy. Laboratory tests revealed the following results:serum creatinine 140-150μmol/ L,albumin 44-46 g,and platelet count(PLT)(129-136)× 109 / L,respectively during the first 4 cycles of treatment. His serum creatinine increased to 192 μmol/ L,albumin decreased to 32 g/ L,and PLT decreased to 69 × 109 / L on the second weeks during the fifth cycle. After the end of drug use during the sixth cycle his serum creatinine increased to 284 μmol/ L,albumin decreased to 25 g/ L and PLT decreased to 56 × 109 / L. On the third week during the seventh cycle his serum creatinine,albumin and PLT were 247μmol/ L,22 g/ L and 71 × 109 / L,respectively. He was diagnosed as kidney injury due to sunitinib. The targeted therapy of sunitinib was stopped. The patient was suggested to visit the Division of Nephrology. According to the advice of doctor in Nephrology,the patient received the targeted therapy again 95 days later. But the dosage of sunitinib was decreased to 37. 5 mg daily,the medication cycle was the same as it was before. The patient's serum creatinine increased during the medication period and decreased during the interval according to the patient's family member's recounting. But the detection values were not clear. Five months later,his serum creatinine increased to 300 μmol/ L,and sunitinib was stopped by himself. Two months later,the patient developed brain metastases and no longer used sunitinib.